+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

This observational study follows patients with relapsing multiple sclerosis RMS who are being treated with approved injectable or selected oral disease-modifying therapies DMTs in Germany. The study is non-interventional and open-label, designed to collect real-world data on treatment and disease progression over several years. It aims to understand how patients continue their baseline treatments and how these treatments impact various health and quality of life measures. Participants receive routine medical care with approved injectable or oral DMTs such as ofatumumab, interferon b21, glatiramer acetate, teriflunomide, dimethyl fumarate, or diroximel fumarate. The study includes two cohorts with up to approximately two years of prospective observation each, with an optional extension allowing up to four years total. Treatment decisions and monitoring follow the patients usual care and physicians discretion, including routine visits and telemedicine options. During the study, participants provide medical history, complete questionnaires, and have data collected on disability status, MRI findings, relapses, and laboratory tests. Researchers assess treatment continuation rates, fatigue, anxiety, depression, quality of life, lesion counts, and relapse rates at multiple time points. Safety and treatment interruptions are also documented. Follow-up is flexible and based on standard care procedures, with data collection occurring throughout the observational periods.

Age: 18Years - 100YearsAll Genders
141 locations
O

Actively Recruiting

Researchers are evaluating the real-world effectiveness, safety, and patient compliance of ribociclib combined with an aromatase inhibitor for adjuvant treatment in patients with hormone receptor-positive, HER2-negative early breast cancer at high risk of recurrence. This observational study also compares ribociclib treatment with abemaciclib plus endocrine therapy and endocrine therapy alone, aiming to better understand treatment decisions and clinical adoption in routine practice. The study is conducted across breast centers and gynecological practices to represent typical healthcare settings. Participants receive treatment based on their physicians clinical judgment without randomization or intervention assignment. The study collects data from patients treated with ribociclib plus aromatase inhibitor with or without luteinizing hormone-releasing hormone LHRH, abemaciclib plus endocrine therapy with or without LHRH, or endocrine therapy alone with or without LHRH. Baseline data and follow-up information on adverse events, quality of life, treatment adherence, and socio-economic factors are gathered over time. During the study, participants undergo assessments including evaluation of invasive disease-free survival up to 36 months, quality of life questionnaires, medication adherence reports, and monitoring of adverse events and treatment changes. Data on reasons for treatment decisions, patient perceptions, and healthcare provider involvement are also collected. The study duration extends up to 39 months to provide a comprehensive overview of treatment impact and patient experience in real-world clinical settings.

Age: 18Years - 100YearsAll Genders
287 locations
O

Actively Recruiting

Researchers are conducting a prospective, observational study to assess asthma control, health-related quality of life HRQL, lung function, and medication use in patients with severe eosinophilic asthma who are treated with benralizumab under routine care in Germany. The study aims to observe how these patients manage their asthma over time and how their treatment impacts their daily lives and health status. Participants receive benralizumab as part of their standard care, with no experimental treatment assigned by the study. The study lasts up to 52 weeks and monitors changes in asthma control using tools like the Asthma Control Test ACT and the Asthma Impairment and Risk Questionnaire AIRQ. Health-related quality of life is measured at baseline and follow-ups using the mini Asthma Quality of Life Questionnaire miniAQLQ. Patients also keep a weekly diary of their asthma medication intake, either on paper or electronically, to track any changes. Throughout the study, participants will have assessments at various time points up to one year after starting benralizumab. These include questionnaires on asthma control and quality of life, lung function tests, and biomarker measurements such as eosinophil levels and exhaled nitric oxide. Researchers analyze changes in medication doses and asthma symptoms, while patients regularly report their experiences. The study focuses on real-world outcomes without altering prescribed treatments, aiming to provide insights into the effects of benralizumab in everyday clinical practice.

Age: 18Years - 120YearsAll Genders
41 locations
R

Actively Recruiting

Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
296 locations
E

Actively Recruiting

Researchers are evaluating the impact of standardized patient coaching on how consistently patients with hormone receptor-positive, HER2-negative early breast cancer take abemaciclib, a prescribed oral therapy. The study aims to find out if coaching based on a recognized teaching tool improves treatment adherence compared to routine care. Participants will provide information through several questionnaires to help answer this question. Participants receive standardized coaching based on the Multinational Association of Supportive Care in Cancer MASCC Oral Agent Teaching Tool MOATT. The coaching is designed to support patients while they take abemaciclib combined with endocrine therapy. The study follows patients for up to one year or until they stop taking abemaciclib permanently, whichever comes first. During the study, participants will complete questionnaires measuring their satisfaction with medicine information, medication adherence, and patient typology at 6 and 12 months after starting therapy. Researchers will monitor the time until patients discontinue abemaciclib as the main outcome. The study includes ongoing assessments to understand how coaching affects treatment persistence and patient experience over the year-long period.

All AgesFEMALEPhase Not Applicable
8 locations
I

Actively Recruiting

Healthy Volunteer

Researchers are conducting an international, prospective, multicenter, non-randomized observational study to confirm the safety and performance of the cervical disc prosthesis MOVE4-C. The study also aims to understand how patients quality of life changes after implantation and to assess the range of motion, which is important for implants that preserve movement. This research focuses on individuals with discopathy, herniated cervical discs, spinal stenoses, or radiculopathy. The study involves a single group of 170 patients who will receive a mono- or bisegmental implantation of the MOVE4-C cervical prosthesis. This device-based intervention is observed without randomization or a comparison group. The research collects clinical and radiological data to evaluate the devices performance over time. There are no placebo or blinded treatments involved. Participants will be followed up from baseline through 24 months after implantation. Researchers will assess improvements in neck disability, arm and neck pain using the Neck Disability Index and Visual Analogue Scales, as well as other health and function measures like the Core Outcome Measure Index, SF-36, EuroQoL, and Japanese Orthopedic Association Score. Range of motion and any adverse events related to the device will be monitored. The study includes clinical visits and evaluations to collect these outcomes and ensure safety throughout the follow-up period.

Age: 18Years +All GendersPhase Not Applicable
7 locations
O

Actively Recruiting

Researchers are evaluating how Dupilumab affects health-related quality of life, patient characteristics, efficacy, and safety in adults with Chronic Obstructive Pulmonary Disease COPD in a real-world setting over 24 months. This non-interventional study observes patients who have started Dupilumab treatment independently of the study, focusing on those with uncontrolled COPD despite standard inhaled therapies and elevated blood eosinophils. Patients receive Dupilumab as prescribed in routine clinical practice, with no treatment assigned by the study itself. The study collects data over two years, documenting changes in COPD symptoms, lung function, exacerbation rates, and safety outcomes as patients continue their usual care. During the study, participants clinical data, including COPD Assessment Test CAT scores, lung function tests, exacerbation frequency, and adverse events, are monitored at regular intervals up to 24 months. Patient-reported outcomes and other health measures are collected to understand Dupilumabs long-term effects in everyday use. The study also gathers information on hospitalizations, workdays missed, and reasons for treatment initiation.

Age: 18Years +All Genders
18 locations
I

Actively Recruiting

Researchers are conducting the CATALINA study, a prospective cohort study within the CICERO collaboration, to collect standardized clinical data and biological samples from patients hospitalized for an acute exacerbation of Chronic Obstructive Pulmonary Disease COPD across 20 centers in Europe and beyond. The goal is to develop a detailed European COPD patient data and biobank to support future clinical trials and improve tools for predicting COPD exacerbations. The study plans to recruit 1000 patients hospitalized for an acute COPD exacerbation and follow them for one year. Data and samples will be collected during six scheduled visits three during hospitalization within 48 hours of admission, at 72 hours, and at discharge and three outpatient visits at 3, 6, and 12 months after inclusion. In case of a first respiratory-related hospital readmission during the study, three additional unscheduled visits will follow the same testing schedule as the initial hospitalization. Participants will undergo clinical assessments, biological sampling, and monitoring at each visit, including evaluations of mortality, hospital care needs, treatment responses, respiratory health scales, mental health questionnaires, comorbidities, and various biomarkers. The study will track these outcomes for one year and aims to expand the data and biobank in future CICERO lifecycles, supporting long-term research efforts in COPD.

Age: 18Years +All Genders
22 locations